Targeting DNA repair weakness in ARID1A‑mutant type I ovarian cancer
Project 3: Investigating new treatment approaches based on DNA repair vulnerability in ARID1A mutated type I ovarian cancer
['FUNDING_OTHER'] · JOHNS HOPKINS UNIVERSITY · NIH-11194325
Looking at whether drugs that take advantage of DNA repair problems can help people with ARID1A‑mutant type I ovarian cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-11194325 on ClinicalTrials.gov |
What this research studies
This project focuses on type I ovarian cancers (clear cell and endometrioid) that often lose the ARID1A protein because of mutations. Researchers will compare cancer cells and engineered precursor cells with and without ARID1A to see if loss of ARID1A causes defects in base excision repair and buildup of DNA damage. They will test treatments in cell and tissue models that exploit those DNA repair weaknesses to see which approaches kill ARID1A‑mutant cancer cells. The lab findings are intended to guide the development of targeted treatment options for patients with these tumor types.
Who could benefit from this research
Good fit: People with type I ovarian cancers (clear cell or endometrioid) whose tumors lack functional ARID1A protein because of ARID1A mutations would be the most relevant candidates.
Not a fit: People whose tumors do not have ARID1A mutations, or who have other ovarian cancer subtypes, are unlikely to benefit from treatments emerging from this project.
Why it matters
Potential benefit: If successful, this work could point to targeted therapies that more effectively treat patients with ARID1A‑mutant type I ovarian cancers.
How similar studies have performed: Laboratory studies have previously indicated ARID1A‑mutant tumors have DNA repair vulnerabilities, but clinical use of therapies targeting this weakness is still emerging.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GAILLARD, STEPHANIE — JOHNS HOPKINS UNIVERSITY
- Study coordinator: GAILLARD, STEPHANIE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers